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Adequate vitamin D levels are necessary for good vascular health. 1,25-dihydroxycholecalciferol activates CYP3A4, an enzyme of
thecytochromeP450system,whichmetabolizesatorvastatintoitsmainmetabolites.Theobjectiveofthisstudywastoevaluatethe
response of cholesterol and triglycerides to atorvastatin according to vitamin D levels. Sixty-three patients with acute myocardial
infarction treated with low and high doses of atorvastatin were included. Levels of total cholesterol, triglycerides, HDL cholesterol,
and LDL cholesterol were measured at baseline and at 12 months of follow-up. Baseline levels of 25-hydroxyvitamin D (25-
OHD) were classiﬁed as deﬁcient (<30nmol/L), insuﬃcient (30–50nmol/L), and normal (>50nmol/L). In patients with 25-OHD
< 30nmol/L, there were no signiﬁcant changes in levels of total cholesterol (173 ±47mg/dL versus 164 ±51mg/dL), triglycerides
(151 ± 49mg/dL versus 177 ± 94mg/dL), and LDL cholesterol (111 ± 48mg/dL versus 92 45±mg/dL); whereas patients with
insuﬃcient (30–50nmol/L) and normal vitamin D (>50nmol/L) had a good response to atorvastatin. We suggest that vitamin D
concentrations >30nmol/L may be required for atorvastatin to reduce lipid levels in patients with acute myocardial infarction.
1.Introduction
Statins, HMG-CoA reductase inhibiters, are eﬀective in the
primary and secondary prevention of cardiovascular disease
and act principally by reducing cholesterol and triglyceride
levels. The relationship between high levels of plasma
cholesterol and atherosclerotic vascular disease is clearly
established, with a reduction in total cholesterol and LDL
cholesterol to below critical levels signiﬁcantly reducing the
risk [1, 2]. The limits for HDL cholesterol and triglycerides
are not so clearly established. Statins are ﬁrst-line agents for
the prevention of vascular risk, with new drugs being added
whentheobjectivesestablishedbyguidelinesarenotreached.
Vitamin D, in addition to increasing intestinal cal-
cium absorption, reducing parathyroid hormone levels and
improving the amount and quality of bone, has a beneﬁcial
vascular eﬀect. Vitamin D deﬁciency has been associated
with peripheral arterial disease and myocardial infarction
[3, 4]. Vitamin D deﬁciency may increase the risk of
cardiovascular disease through three possible mechanisms.
Firstly, in vitro studies have shown that vitamin D may cause
an imbalance between anti-inﬂammatory and proinﬂam-
matory cytokines, reducing NF-κB activity, increasing IL-10
production, and reducing levels of IL-6, IL-1, interferon γ,
and TNFα [5]. Secondly, endothelial cells have receptors for
vitamin D whose stimulation inhibits cell proliferation [6].
Thirdly, the association between hypertension and vitamin
D deﬁcit is mediated by activation of the renin-angiotensin-
aldosterone system. High calcitriol levels reduce plasma
renin activity, leading to reduced plasma angiotensin II
concentrations. This modulation of the renin-angiotensin-
aldosterone system, in addition to reducing blood pressure,
reduces inﬂammation of the vascular endothelium, thus
limiting atherosclerosis progression [7]. Therefore, adequate
vitamin D levels are necessary for good vascular health.
In addition, 1,25-dihydroxycholecalciferol, the active
metabolite of vitamin D, bonds with the vitamin D receptor,2 International Journal of Endocrinology
activating CYP3A4, an enzyme of the cytochrome P450 sys-
tem, which metabolizes atorvastatin to its main metabolites
[8]. Therefore, low vitamin D levels might reduce CYP3A4
activity, increasing atorvastatin levels and making it more
eﬀective in reducing cholesterol and triglyceride levels.
The objective of this study was to evaluate the response




tion were eligible for inclusion. Patients were recruited
at hospital admission. Exclusion criteria were alcoholism,
neoplasia, hyper- or hypocalcemia, and treatment with
vitamin D, alendronate, risedronate, zoledronate, raloxifene,
PTH1-34, strontium ranelate,o restrogens. After diagnosis,
patients received low (10–20mg) or high doses (40–80mg)
of atorvastatin as secondary prevention according to baseline
levels of cholesterol and triglycerides and the index of
vascular risk in accordance with the Score chart calibrated
for the Spanish population [9]. Only patients completing
follow-up were evaluated. Patients were classiﬁed according
to levels of 25-hydoxyvitamin D (25-OHD) as deﬁcient (25-
OHD <30nmol/L), insuﬃcient (30nmol/L–50nmol/L), and
normal (>50nmol/L) [10].
Blood samples were obtained after 8 hours of fast-
ing in the ﬁrst three days after admission. Cholesterol,
triglyceride, HDL cholesterol, and phosphatase levels were
measured using a Hitachi 917 autoanalyser (Tokyo, Japan).
LDL cholesterol was calculated by an indirect method. 25-
OHD levels were determined by high-performance liquid
chromatography with a 12% interassay variation coeﬃcient.
A descriptive statistical analysis was made, including
measures of central tendency and scattering for quantitative
variables. The Student’s t-test was used to compare variables
and the Anova test for multiple comparisons. Results are
expressed as mean ± standard deviation; the level of
statistical signiﬁcance was established as P = .05. The study
was approved by the clinical research committee of the
hospital and all patients gave written informed consent to
participate in the study.
3. Results andDiscussion
Sixty-three patients with acute myocardial infarction (40
males and 23 females) with ages ranging between 37 and
79 years were included. All females were postmenopausal.
2 5 - O H Dl e v e l sa tb a s e l i n ew e r e<30nmol/L in 13 patients,
30–50nmol/L in 34, and >50nmol/L in 16 patients. Baseline
patient characteristics showed no signiﬁcant diﬀerences
between groups, although 76% of patients with 25-OHD
<30nmol/L have received high doses of atorvastatin. There
werenosigniﬁcantdiﬀerencesbetweenthethreegroupswith
respect to the distribution of the doses (Table 1).
Table 2 shows the response to atorvastatin at 12 months
according to vitamin D levels. In patients with 25-OHD
<30nmol/L, there was no reduction in levels of total
cholesterol, triglycerides, and LDL cholesterol but there was
a signiﬁcant rise in levels of HDL cholesterol. Patients with
insuﬃcient and normal vitamin D levels had the expected
response, with a reduction in levels of total cholesterol,
triglycerides, LDL cholesterol, and elevation of HDL. There
were no diﬀerences in the response according to gender or
the dose of atorvastatin used, with total cholesterol levels
falling in patients receiving high doses (181 ± 49 versus 157
± 39, P = .0008) and low doses (188 ± 45 versus 169 ± 41,
P = .02).
Our results show that the reduction in levels of choles-
terol and triglycerides was signiﬁcantly greater in patients
with insuﬃcient and normal vitamin D levels compared to
those with deﬁcient levels. Other authors have shown an
added eﬀect of vitamin D, not only on levels of cholesterol
and triglycerides but also on the prevalence of cardiovascular
disease [11].
The eﬃcacy of atorvastatin depends on its plasma
concentrations and those of its hydroxylated metabolites.
Atorvastatin has low oral bioavailability due to rapid hepatic
and renal metabolization by enzymes of the P450 system,
mainly CYP3A4-1 [12]. This system is a nexus of union
between statins and vitamin D. Bonding of the active
metabolite of vitamin D brings about a change in the
conformation of the receptor, which is closely linked to the
X receptor of retinoic acid, forming a heterodimer [13].
This activates gene transcription, facilitating the synthesis of
speciﬁc proteins, including the enzymes of the cytochrome
P450 system (CYP3A11, CYP3A1, and CYP3A4) [14].
These enzymes participate in the oxidation of atorvastatin,
giving rise to the synthesis of two active metabolites, 2-
hydroxyatorvastatin and 4-hydroxyatorvastatin [15]. Vita-
min D induces P450, reducing concentrations of atorvastatin
and its active metabolites, as shown by Schwartz [16], who
studied the eﬀects of vitamin D supplements on atorvastatin
concentrations and cholesterol in 16 healthy volunteers.
Vitamin D induced CYP3A4, reducing active concentrations
of atorvastatin and its metabolites. This reduction should
produceanincreaseincholesterolandLDLcholesterollevels.
However, the inverse was observed, with a fall in total
cholesterol and LDL cholesterol levels. These data reﬂect our
ﬁndings.
The enzyme, 3-hydro-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, plays a key role regulating the
synthesis of cholesterol. Hydroxylation of sterols generates
a powerful inhibition of reductase activity. Defay et al. [17]
found that hydroxylated vitamin D derivatives inhibited
HMG-CoA reductase activity in lymphocytes stimulated
with phytohemaglutinin. Experimental studies in various
cell lines have shown that treatment with cholecalciferol
(vitamin D3) and its metabolites (25-hydroxycholecalciferol,
1,25-dihydroxycholecalciferol, and24, 25- dihydroxychole-
calciferol) inhibit cholesterol synthesis due to inhibition
of the activity of HMG-CoA reductase, a key enzyme in
cholesterol synthesis. This eﬀect is not produced by the
active metabolite of vitamin D, 1,25-dihydoxyvitamin D
[18]. The inhibition of enzyme activity was concentration
dependent. In addition, 25-hydroxyvitamin D3 can inhibits
lanosterol 14α- demethylase (CYP51A1), an enzyme whichInternational Journal of Endocrinology 3
Table 1: Baseline patient characteristics according to vitamin D levels. High doses: atorvastatin (40–80mg). Low doses: atorvastatin (10–
20mg).
Vitamin D <30, Vitamin D 30–50, Vitamin D >50, P
nmol/L (n = 13) nmol/L (n = 34) nmol/L (n = 16)
Age (years) 61 ± 11 61 ± 10 62 ± 10 0.981
Weight (kg) 75 ± 10 75 ± 12 72 ± 10 0.552
Height (cm) 167 ± 8 163 ± 9 164 ± 9 0.482
High doses 10 14 10 0.072
Low doses 3 20 6 0.060
Male/female 9/4 20/14 11/5 0. 706
Table 2: Vitamin D levels and response to atorvastatin.
Vitamin D <30, Vitamin D 30–50, Vitamin D >50,
nmol/L (n = 13) nmol/L (n = 34) nmol/L (n = 16)
Baseline 12m Baseline 12m Baseline 12m
Cholesterol mg/dL 173 ± 47 164 ± 51 177 ± 49 157 ± 31b 202 ± 43 163 ± 25e
Triglycerides mg/dL 151 ± 49 177 ± 94 154 ± 121 114 ± 55 157 ± 61 110 ± 37f
HDL cholesterol mg/dL 34 ± 64 5 ± 9a 36 ± 11 49 ± 13c 41 ± 85 0 ± 10g
LDL cholesterol mg/dL 111 ± 48 92 ± 45 112 ± 42 86 ± 31d 114 ± 29 89 ± 26h
(a) P = .001, (b) P = .021, (c) P = .0001, (d) P = .01, (e) P = .003, (f) P = .0001, (g) P = .008, (h) P = .022.
also intervenes in the synthesis of cholesterol. A deﬁcit
of 25-hydroxycholecalciferol increases both reductase and
CYP51A1 activity, raising cholesterol levels. Atorvastatin acts
on this enzyme, and therefore it may be hypothesised that
a speciﬁc concentration of vitamin D is required for it
to synergize with the statin and exert its eﬀect on lipid
metabolism.
In a previous study, we found an increase in 25-
hydroxyvitamin D levels after a year of treatment with ator-
vastatin, with a reduction in the number of patients deﬁcient
in this hormone [4]. Similar ﬁndings have been observed
in two small studies including 18 patients with familiar
hypercholesterolemia, where the administration of statins
(lovastatin, simvastatin) resulted in rises in serum concen-
trations of vitamin D [19, 20]. The mechanism responsible
was related to the inhibition of 3-hydroxy-3 methylglutaryl
coenzyme A (HMG-CoA) reductase which catalyzes 7-
dehydrocholesterol to cholesterol. 7-dehidrocholesterol is a
precursor not only of cholesterol but also of vitamin D
[21]. Enzyme blockade may divert 7-dehidrocolesterol to the
synthesis of cholecalciferol, raising its concentration. This
increase might explain part of the beneﬁcial eﬀect of statins
on bone metabolism, the increase in bone mineral density,
and the reduction in the number of fractures.
These data contribute new insight on the extraskeletal
action of vitamin D. Pilz et al. [22] recently showed that
vitamin D deﬁciency was associated with an increase in
cardiovascular mortality due to heart failure or sudden death
in 3229 patients referred for coronary angiography. After
adjusting for vascular risk factors, patients with vitamin D
<25nmol/L had a threefold greater risk of death due to heart
failure and a ﬁvefold greater risk of sudden death during
the seven-year follow-up. Other reports show similar results
[23].
4. Conclusion
Although the study sample is small, our results suggest
that plasma 25-OHD concentrations above 30nmol/L are
required for atorvastatin to reduce levels of total cholesterol,
triglycerides, and LDL cholesterol in patients with acute
myocardial infarction.
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